Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Sheep tissue device could improve breast reconstruction safety

NCT ID NCT07135596

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a device called OviTex PRS, made from sheep stomach tissue and polymer thread, for women having breast reconstruction after mastectomy. The goal is to see if it is safe and effective at reducing complications like reconstructive failure. About 235 women will take part in this research.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
OviTex PRS (a device made from sheep stomach tissue and polymer thread, used to support breast reconstruction)
What this could lead to
If successful, this could provide a safer, more effective option for women undergoing breast reconstruction after mastectomy.
What could go wrong
This is an early-stage study without a control group, so results may not be definitive. There is a risk of complications like reconstructive failure or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 235 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Jun 2034

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 to 75 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient is a female between the ages of 22 - 75, inclusive, at the time of enrollment (e.g. date of index surgical procedure); 2. Patient is planned for a first-time immediate unilateral or bilateral DTI pre-pectoral breast reconstruction following mastectomy for cancer or as cancer prophylaxis; 3. Patient is not a current cigarette smoker; 4. Patient is willing and able to voluntarily sign the IRB approved Subject Informed Consent Form; 5. Patient is willing and able to comply with the study requirements including completion of required follow-up visits, subject questionnaires, clinic evaluations, and photographs. Exclusion Criteria: 1. Patient has a BMI \< 18.5 or \> 35; 2. Patient is undergoing radical mastectomy; 3. Breast reconstruction plan includes hybrid implant coverage using another type of mesh (synthetic or ADM) or another autologous treatment such as large latissimus flap, abdominal flap or similar; 4. Breast reconstruction plan includes a custom sized breast implant, permanent breast implant greater than 800cc, and/or a permanent breast implant that is not FDA approved for use in breast reconstruction; 5. Patient has undergone prior breast reconstruction, breast augmentation, mastopexy, or breast reduction surgeries (not including breast biopsy); 6. Patient is undergoing delayed reconstruction; 7. Patient has received neo-adjuvant radiation to the chest (including any previous history of whole breast radiation or mantle radiation); 8. Patient has received neo-adjuvant chemotherapy within the 4 weeks prior to enrollment; 9. Patient has received Keytruda therapy or is planning to receive Keytruda therapy during study participation; 10. Patient has uncontrolled Type I or Type II diabetes (HbA1C \>7%); 11. Patient is pregnant or planning to become pregnant during study participation and up to 5 years from the index surgical procedure; • If the subject is not post-menopausal, agree to take adequate birth control precautions during study participation; 12. Patient has been diagnosed with a medical condition or is taking medications which are known to impact wound healing, weaken the body's natural resistance to disease, result in elevated postoperative risks, or may otherwise affect the validity of the study; 13. Patient has a known sensitivity or allergy to poly(lactic-co-glycolic acid) (PLGA) or materials of ovine (sheep) origin; 14. Patient is diagnosed with a bleeding disorder in which medication is not stopped within 2 weeks of the index procedure; 15. Patient is currently diagnosed with drug or alcohol abuse or has a known history with relapse within the past 3 years; 16. Patient is currently participating in another drug or device clinical trial; 17. Patient is currently imprisoned. Intraoperative Exclusion Criteria All subjects will be evaluated intraoperatively for the following exclusion criteria: 1. Subject does not receive an immediate pre-pectoral direct-to-implant breast reconstruction; 2. Study device will not be used during the procedure or a non-eligible device will be implanted.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast reconstruction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Qualmedica Research

    RECRUITING

    Bowling Green, Kentucky, 42101, United States

  • WakeMed

    RECRUITING

    Raleigh, North Carolina, 27610, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.